Cargando…
Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy?
Serum tumor markers are useful to evaluate a cancer's response to treatment, for early detection of cancer relapse, and, in some cases, to diagnose malignancy. In this paper, we present two patients with significantly elevated serum tumor markers without evidence of malignant disease. An 18-yea...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132476/ https://www.ncbi.nlm.nih.gov/pubmed/21760772 http://dx.doi.org/10.1155/2011/123743 |
_version_ | 1782207828627292160 |
---|---|
author | van der Veek, Patrick P. J. de Vos tot Nederveen Cappel, Wouter H. Langers, Alexandra M. J. van Hoek, Bart |
author_facet | van der Veek, Patrick P. J. de Vos tot Nederveen Cappel, Wouter H. Langers, Alexandra M. J. van Hoek, Bart |
author_sort | van der Veek, Patrick P. J. |
collection | PubMed |
description | Serum tumor markers are useful to evaluate a cancer's response to treatment, for early detection of cancer relapse, and, in some cases, to diagnose malignancy. In this paper, we present two patients with significantly elevated serum tumor markers without evidence of malignant disease. An 18-year-old patient suffering from autoimmune hepatitis had markedly increased alpha-fetoprotein (aFP) levels (2,002 μg/L; normal <10 ug/L). Extensive imaging showed no signs of hepatocellular carcinoma or other cancer, and treatment with Prednisone led to rapid normalization of both liver enzymes and aFP. The second patient, a 60-year-old female with painless jaundice due to biliary stone disease, had very high serum levels of CA19-9 (18,000 kU/L, normal <27 kU/L). Liver biochemistry and serum CA19-9 concentration decreased to almost normal values (45 kU/L) after biliary stenting. These cases demonstrate that serum tumor markers can be elevated in benign disease and are therefore not appropriate to diagnose cancer. |
format | Online Article Text |
id | pubmed-3132476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31324762011-07-14 Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy? van der Veek, Patrick P. J. de Vos tot Nederveen Cappel, Wouter H. Langers, Alexandra M. J. van Hoek, Bart Gastroenterol Res Pract Case Report Serum tumor markers are useful to evaluate a cancer's response to treatment, for early detection of cancer relapse, and, in some cases, to diagnose malignancy. In this paper, we present two patients with significantly elevated serum tumor markers without evidence of malignant disease. An 18-year-old patient suffering from autoimmune hepatitis had markedly increased alpha-fetoprotein (aFP) levels (2,002 μg/L; normal <10 ug/L). Extensive imaging showed no signs of hepatocellular carcinoma or other cancer, and treatment with Prednisone led to rapid normalization of both liver enzymes and aFP. The second patient, a 60-year-old female with painless jaundice due to biliary stone disease, had very high serum levels of CA19-9 (18,000 kU/L, normal <27 kU/L). Liver biochemistry and serum CA19-9 concentration decreased to almost normal values (45 kU/L) after biliary stenting. These cases demonstrate that serum tumor markers can be elevated in benign disease and are therefore not appropriate to diagnose cancer. Hindawi Publishing Corporation 2011 2011-06-16 /pmc/articles/PMC3132476/ /pubmed/21760772 http://dx.doi.org/10.1155/2011/123743 Text en Copyright © 2011 Patrick P. J. van der Veek et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report van der Veek, Patrick P. J. de Vos tot Nederveen Cappel, Wouter H. Langers, Alexandra M. J. van Hoek, Bart Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy? |
title | Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy? |
title_full | Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy? |
title_fullStr | Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy? |
title_full_unstemmed | Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy? |
title_short | Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy? |
title_sort | two patients with extremely elevated tumor markers: where is the malignancy? |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132476/ https://www.ncbi.nlm.nih.gov/pubmed/21760772 http://dx.doi.org/10.1155/2011/123743 |
work_keys_str_mv | AT vanderveekpatrickpj twopatientswithextremelyelevatedtumormarkerswhereisthemalignancy AT devostotnederveencappelwouterh twopatientswithextremelyelevatedtumormarkerswhereisthemalignancy AT langersalexandramj twopatientswithextremelyelevatedtumormarkerswhereisthemalignancy AT vanhoekbart twopatientswithextremelyelevatedtumormarkerswhereisthemalignancy |